XL MECOM 3q26 consists of an orange-labeled probe hybridizing proximal to the MECOM gene region at 3q26.2 and a green-labeled probe hybridizing distal to the MECOM gene region also spanning a distal part of the gene region at 3q26.2.

Probe maps for selected products have been updated. These updates ensure a consistent presentation of all gaps larger than 10 kb including adjustments to markers, genes, and related elements. This update does not affect the device characteristics or product composition. Please refer to the list to find out which products now include updated probe maps.

Probe map details are based on UCSC Genome Browser GRCh37/hg19, with map components not to scale.

Myelodysplastic syndromes and myeloproliferative disorders are associated with deregulated production of myeloid cells. According to WHO classification (2008), cytogenetic aberrations are observed in about 50% of MDS cases. The most common aberrations are 5q-, 7/7q-, trisomy 8, del(20q), and inv(3) or t(3;3).

Chromosomal translocations involving the EVI1 locus are a recurrent finding in myeloid leukemia and are associated with poor prognosis. Two common recurrent rearrangements affect the 3q26 locus. One is the inv(3)(q21q26) and the translocation t(3;3)(q21;q26), in which EVI1 overexpression is caused by juxtaposition of the EVI1 gene to enhancer elements of the Ribophorin gene at 3q21. EVI1 activation is also observed in the translocations t(3;12)(q26;p13) and t(3;21)(q26;q22) and is due to generation of the fusion genes ETV6/EVI1 and RUNX1/EVI1, respectively.

Clinical Applications

• Acute Myelogenous Leukemia (AML)
• Myelodysplastic Syndrome (MDS)

XL MECOM 3q26 hybridized to lymphocytes. One normal metaphase and one normal interphase are shown.

• Lugthart et al (2008) Blood 111:4329-4337
• De Melo et al (2008) Leukemia 22:434-437
• De Braekeleer et al (2011) Anticancer Res 31:3441-3448